Kalos Management, Inc. Mirati Therapeutics, Inc. Transaction History

Kalos Management, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$47.1 - $62.7 $388,575 - $517,275	-8,250 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$26.05 - $52.4 $214,912 - $432,300	8,250 New	8,250 $252,000
Q1 2018 May 14, 2018	SELL	$17.2 - $34.95 $215,860 - $438,622	-12,550 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$12.65 - $19.0 $632 - $950	50 Added 0.4%	12,550 $232,000
Q3 2017 Nov 14, 2017	SELL	$4.7 - $11.7 $7,050 - $17,550	-1,500 Reduced 10.71%	12,500 $146,000
Q2 2017 Aug 15, 2017	BUY	N/A	14,000	14,000 $51,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Kalos Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kalos Management, Inc. with notifications on news.